About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Prostate Cancer Clinical Trials in Los Angeles | 141 Studies

Clinical Trials Prostate CancerLos Angeles

Prostate Cancer Clinical Trials in Los Angeles

Find 141 clinical trials for prostate cancer near Los Angeles, California. Connect with research centers in your area.

All Prostate Cancer trials nationwide All trials in Los Angeles

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 101-120 of 141 trials

Active not recruitingA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with…NCT04497844·Homewood, Alabama and 386 others

Prostate Cancer Trials in Other Cities

New York Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedA Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane RegimenThis Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) in…NCT03016312·Duarte, California and 157 others

CompletedStudy of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate CancerSGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere.NCT00031187·Tucson, Arizona and 10 others

RecruitingLongitudinal Advanced Prostate Cancer Cohort (LAPCC)This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…NCT06067295·Los Angeles, California and 1 other

Active not recruitingTesting the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyThis phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with…NCT05053152·Phoenix, Arizona and 244 others

RecruitingRandomized Phase II Trial of Targeted Radiation With no Castration for McrpcThis trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy)…NCT06084338·West Los Angeles, California and 3 others

UnknownEnzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate CancerThis randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant…NCT01949337·Birmingham, Alabama and 538 others

CompletedRadiation Therapy in Treating Patients With Stage II or Stage III Prostate CancerRATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.NCT00002602·Birmingham, Alabama and 227 others

Active not recruitingAbiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsThis is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC).NCT03012321·Los Angeles, California and 15 others

UnknownEarly Prostate Cancer: Predicting Treatment ResponseThis study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient…NCT03770351·Irvine, California and 4 others

CompletedProspective Assessment of Image Registration for the Diagnosis of Prostate CancerThis is a pilot study to determine cancer detection rate of conventional/systematic versus targeted biopsy methods in diagnosis of potentially lethal prostate cancer.NCT02425228·Los Angeles, California and 1 other

CompletedA Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYXThis is a multi-center, prospective, observational study of patients being treated with ORGOVYX.NCT05467176·Homewood, Alabama and 95 others

Active not recruitingCopper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerThis is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate…NCT06235151·Homewood, Alabama and 42 others

CompletedFocal Laser Ablation of Prostate CancerThe primary objective of this study is to evaluate the safety and feasibility of Magnetic-Resonance(MR)-ultrasound image fusion-guided transrectal-based focal laser ablation (FLA)…NCT04305925·Los Angeles, California

TerminatedDocetaxel and Carboplatin for Patients With mCRPC and DNA-Repair DeficienciesIn this study, patients who have metastatic prostate cancer that does not respond to hormone treatment and who have mutations in certain cancer-related genes will be treated with…NCT02985021·Los Angeles, California and 2 others

CompletedOnce-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with…NCT02445976·Birmingham, Alabama and 20 others

CompletedFocal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate LesionsThe hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined…NCT01657942·Duarte, California and 8 others

CompletedEffect of Weight Loss on Prostate Cancer PathologyThe purpose of this study is to determine if weight loss prior to radical prostatectomy effects chemical substances in the blood stream and prostate tissue that may affect…NCT00475982·West Los Angeles, California

Active not recruitingA Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate CancerMen with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this…NCT05027477·Chandler, Arizona and 21 others

CompletedA Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsStudy CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019).NCT05293496·Los Angeles, California and 9 others

PreviousPage 6 of 8Next

Other Conditions in Los Angeles

Breast Cancer Lung Cancer Colorectal Cancer Melanoma Leukemia Lymphoma